What's Happening?
Standing Ovation, a French startup, has successfully raised €25 million ($28.5 million) in a Series B funding round, along with an additional €5 million ($5.7 million) in non-dilutive funding. The funding aims to accelerate the commercialization of casein
proteins in North America by 2026, with plans to expand into Europe and Asia by late 2027. The company utilizes a patented process that uses acid whey as the primary carbon source in its feedstock, differentiating it from other firms in the precision fermentation space. Standing Ovation is working with contract manufacturing organizations in Eastern Europe and India, and has partnerships with Ajinomoto and Tetra Pak for large-scale production and downstream processing.
Why It's Important?
The development of casein proteins through precision fermentation represents a significant advancement in the alternative protein market. Standing Ovation's approach could lead to more sustainable and cost-effective production methods, reducing reliance on traditional dairy farming. This innovation aligns with growing consumer demand for plant-based and environmentally friendly products. The company's partnerships with industry leaders like Ajinomoto and Tetra Pak further enhance its potential to scale production efficiently, potentially transforming the dairy industry and offering new opportunities for food sovereignty and CO2 reduction.
What's Next?
Standing Ovation plans to secure a 'no questions' letter from the FDA by the end of 2026 to affirm the GRAS status of its proteins. The company is also submitting a novel foods dossier to the European Food Safety Authority, aiming for EU approval by the end of 2027. As the company continues to develop its technology and expand its market presence, it may face challenges related to regulatory approvals and competition from other firms in the precision fermentation space.
